Validity of EQ‐5D‐5L, Skindex‐16, DLQI and DLQI‐R in patients with hidradenitis suppurativa

Background Numerous generic, skin‐ and disease‐specific health‐related quality of life (HRQoL) measures are available for patients with hidradenitis suppurativa (HS). Yet, robust psychometric evidence is lacking in many aspects of these outcome measures. Objectives We sought to determine convergent...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the European Academy of Dermatology and Venereology 2020-11, Vol.34 (11), p.2584-2592
Hauptverfasser: Gergely, L.H., Gáspár, K., Brodszky, V., Kinyó, Á., Szegedi, A., Remenyik, É., Kiss, N.F., Bató, A., Péntek, M., Gulácsi, L., Sárdy, M., Bánvölgyi, A., Wikonkál, N., Rencz, F.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2592
container_issue 11
container_start_page 2584
container_title Journal of the European Academy of Dermatology and Venereology
container_volume 34
creator Gergely, L.H.
Gáspár, K.
Brodszky, V.
Kinyó, Á.
Szegedi, A.
Remenyik, É.
Kiss, N.F.
Bató, A.
Péntek, M.
Gulácsi, L.
Sárdy, M.
Bánvölgyi, A.
Wikonkál, N.
Rencz, F.
description Background Numerous generic, skin‐ and disease‐specific health‐related quality of life (HRQoL) measures are available for patients with hidradenitis suppurativa (HS). Yet, robust psychometric evidence is lacking in many aspects of these outcome measures. Objectives We sought to determine convergent and known‐groups validity of multiple generic and skin‐specific HRQoL measures and to identify predictors of impaired HRQoL in patients with HS. Methods Between 2017 and 2019, a multicentre cross‐sectional study was carried out involving 200 consecutive HS patients. HRQoL outcomes included the EQ‐5D‐5L, EQ visual analogue scale (EQ VAS), Skindex‐16, Dermatology Life Quality Index (DLQI) and DLQI‐Relevant (DLQI‐R). Disease severity was graded by HS‐Physician’s Global Assessment (HS‐PGA) scale and the Modified Sartorius scale (MSS). Results Overall, 77%, 56%, 51%, 46% and 28% reported problems in the pain/discomfort, usual activities, anxiety/depression, mobility and self‐care dimensions of EQ‐5D‐5L. Mean ± SD EQ VAS, DLQI and DLQI‐R scores were 64.29 ± 22.68, 11.75 ± 8.11 and 12.19 ± 8.33, respectively. Skindex‐16 responses indicated that the emotional burden of HS (64.55 ± 29.28) far exceeded those of functioning (49.40 ± 34.70) and physical symptoms (46.74 ± 29.36). EQ‐5D‐5L, EQ VAS, DLQI, DLQI‐R and Skindex‐16 total scores had moderate or strong correlations with each other (range: |0.487| to |0.993|), weak or moderate correlations with HS‐PGA (|0.350| to |0.433|) and weak correlations with MSS (|0.324| to |0.389|). DLQI‐R slightly outperformed DLQI both in terms of convergent and known‐groups validity. Being female, lower education level, more severe disease and genital involvement were associated with worse HRQoL (P < 0.05). Conclusion This study provides high‐quality evidence that among skin‐specific outcomes, the DLQI, DLQI‐R and Skindex‐16, and among generic instruments, the EQ‐5D‐5L are suitable to be used in HS patients. In future research, we recommend the use of existing well‐validated HRQoL tools instead of developing new measures for each study. The development of composite measures that combine physician‐ and patient‐reported outcomes is not supported by evidence in HS. [Correction added on 25 July 2020, after first online publication: in the section, the ± signs were missing and have been added to this version.]
doi_str_mv 10.1111/jdv.16642
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2420140283</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2420140283</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3602-53c4ca33e2539e355a4881ffdb03faf61995360c9ee441ddd401ec09764989743</originalsourceid><addsrcrecordid>eNp1kMtOwkAUhidGI4gufAEzS00ozK1DZ2kAFdPE4IVtM3SmYbC0tdOK7HwEn9EncaDozrM41y9_cn4AzjHqYRf9pXrvYc4ZOQBtzHjgURTQQ9BGgnBPCF-0wIm1S4QQxn5wDFqUcBwgQtognsnUKFNtYJ7A8fT788sfbVPYhU-vJlP6w02Yd-EonE6gzNSucbtHaDJYyMrorLJwbaoFXBhVSqUzUxkLbV0Udenu7_IUHCUytfpsXzvg5Wb8PLzzwofbyfA69GLKEfF8GrNYUqqJT4Wmvi9ZEOAkUXNEE5lw7D5xYCy0ZgwrpRjCOkZiwJkIxIDRDrhsdIsyf6u1raKVsbFOU5npvLYRYQRhhkhAHXrVoHGZW1vqJCpKs5LlJsIo2noaOU-jnaeOvdjL1vOVVn_kr4kO6DfA2qR6879SdD-aNZI_QEuBbQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2420140283</pqid></control><display><type>article</type><title>Validity of EQ‐5D‐5L, Skindex‐16, DLQI and DLQI‐R in patients with hidradenitis suppurativa</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Gergely, L.H. ; Gáspár, K. ; Brodszky, V. ; Kinyó, Á. ; Szegedi, A. ; Remenyik, É. ; Kiss, N.F. ; Bató, A. ; Péntek, M. ; Gulácsi, L. ; Sárdy, M. ; Bánvölgyi, A. ; Wikonkál, N. ; Rencz, F.</creator><creatorcontrib>Gergely, L.H. ; Gáspár, K. ; Brodszky, V. ; Kinyó, Á. ; Szegedi, A. ; Remenyik, É. ; Kiss, N.F. ; Bató, A. ; Péntek, M. ; Gulácsi, L. ; Sárdy, M. ; Bánvölgyi, A. ; Wikonkál, N. ; Rencz, F.</creatorcontrib><description>Background Numerous generic, skin‐ and disease‐specific health‐related quality of life (HRQoL) measures are available for patients with hidradenitis suppurativa (HS). Yet, robust psychometric evidence is lacking in many aspects of these outcome measures. Objectives We sought to determine convergent and known‐groups validity of multiple generic and skin‐specific HRQoL measures and to identify predictors of impaired HRQoL in patients with HS. Methods Between 2017 and 2019, a multicentre cross‐sectional study was carried out involving 200 consecutive HS patients. HRQoL outcomes included the EQ‐5D‐5L, EQ visual analogue scale (EQ VAS), Skindex‐16, Dermatology Life Quality Index (DLQI) and DLQI‐Relevant (DLQI‐R). Disease severity was graded by HS‐Physician’s Global Assessment (HS‐PGA) scale and the Modified Sartorius scale (MSS). Results Overall, 77%, 56%, 51%, 46% and 28% reported problems in the pain/discomfort, usual activities, anxiety/depression, mobility and self‐care dimensions of EQ‐5D‐5L. Mean ± SD EQ VAS, DLQI and DLQI‐R scores were 64.29 ± 22.68, 11.75 ± 8.11 and 12.19 ± 8.33, respectively. Skindex‐16 responses indicated that the emotional burden of HS (64.55 ± 29.28) far exceeded those of functioning (49.40 ± 34.70) and physical symptoms (46.74 ± 29.36). EQ‐5D‐5L, EQ VAS, DLQI, DLQI‐R and Skindex‐16 total scores had moderate or strong correlations with each other (range: |0.487| to |0.993|), weak or moderate correlations with HS‐PGA (|0.350| to |0.433|) and weak correlations with MSS (|0.324| to |0.389|). DLQI‐R slightly outperformed DLQI both in terms of convergent and known‐groups validity. Being female, lower education level, more severe disease and genital involvement were associated with worse HRQoL (P &lt; 0.05). Conclusion This study provides high‐quality evidence that among skin‐specific outcomes, the DLQI, DLQI‐R and Skindex‐16, and among generic instruments, the EQ‐5D‐5L are suitable to be used in HS patients. In future research, we recommend the use of existing well‐validated HRQoL tools instead of developing new measures for each study. The development of composite measures that combine physician‐ and patient‐reported outcomes is not supported by evidence in HS. [Correction added on 25 July 2020, after first online publication: in the section, the ± signs were missing and have been added to this version.]</description><identifier>ISSN: 0926-9959</identifier><identifier>EISSN: 1468-3083</identifier><identifier>DOI: 10.1111/jdv.16642</identifier><identifier>PMID: 32618022</identifier><language>eng</language><publisher>England</publisher><subject>Cross-Sectional Studies ; Female ; Hidradenitis Suppurativa ; Humans ; Psychometrics ; Quality of Life ; Surveys and Questionnaires</subject><ispartof>Journal of the European Academy of Dermatology and Venereology, 2020-11, Vol.34 (11), p.2584-2592</ispartof><rights>2020 The Authors. published by John Wiley &amp; Sons Ltd on behalf of European Academy of Dermatology and Venereology</rights><rights>2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Dermatology and Venereology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3602-53c4ca33e2539e355a4881ffdb03faf61995360c9ee441ddd401ec09764989743</citedby><cites>FETCH-LOGICAL-c3602-53c4ca33e2539e355a4881ffdb03faf61995360c9ee441ddd401ec09764989743</cites><orcidid>0000-0002-7071-1364 ; 0000-0001-6530-7052 ; 0000-0003-2109-9014 ; 0000-0003-4306-5093 ; 0000-0002-0973-5228 ; 0000-0002-1450-4790 ; 0000-0002-6095-2295 ; 0000-0001-5266-4667 ; 0000-0001-9674-620X ; 0000-0001-9636-6012 ; 0000-0002-9285-8746 ; 0000-0002-9947-1755 ; 0000-0003-4949-8711</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjdv.16642$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjdv.16642$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32618022$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gergely, L.H.</creatorcontrib><creatorcontrib>Gáspár, K.</creatorcontrib><creatorcontrib>Brodszky, V.</creatorcontrib><creatorcontrib>Kinyó, Á.</creatorcontrib><creatorcontrib>Szegedi, A.</creatorcontrib><creatorcontrib>Remenyik, É.</creatorcontrib><creatorcontrib>Kiss, N.F.</creatorcontrib><creatorcontrib>Bató, A.</creatorcontrib><creatorcontrib>Péntek, M.</creatorcontrib><creatorcontrib>Gulácsi, L.</creatorcontrib><creatorcontrib>Sárdy, M.</creatorcontrib><creatorcontrib>Bánvölgyi, A.</creatorcontrib><creatorcontrib>Wikonkál, N.</creatorcontrib><creatorcontrib>Rencz, F.</creatorcontrib><title>Validity of EQ‐5D‐5L, Skindex‐16, DLQI and DLQI‐R in patients with hidradenitis suppurativa</title><title>Journal of the European Academy of Dermatology and Venereology</title><addtitle>J Eur Acad Dermatol Venereol</addtitle><description>Background Numerous generic, skin‐ and disease‐specific health‐related quality of life (HRQoL) measures are available for patients with hidradenitis suppurativa (HS). Yet, robust psychometric evidence is lacking in many aspects of these outcome measures. Objectives We sought to determine convergent and known‐groups validity of multiple generic and skin‐specific HRQoL measures and to identify predictors of impaired HRQoL in patients with HS. Methods Between 2017 and 2019, a multicentre cross‐sectional study was carried out involving 200 consecutive HS patients. HRQoL outcomes included the EQ‐5D‐5L, EQ visual analogue scale (EQ VAS), Skindex‐16, Dermatology Life Quality Index (DLQI) and DLQI‐Relevant (DLQI‐R). Disease severity was graded by HS‐Physician’s Global Assessment (HS‐PGA) scale and the Modified Sartorius scale (MSS). Results Overall, 77%, 56%, 51%, 46% and 28% reported problems in the pain/discomfort, usual activities, anxiety/depression, mobility and self‐care dimensions of EQ‐5D‐5L. Mean ± SD EQ VAS, DLQI and DLQI‐R scores were 64.29 ± 22.68, 11.75 ± 8.11 and 12.19 ± 8.33, respectively. Skindex‐16 responses indicated that the emotional burden of HS (64.55 ± 29.28) far exceeded those of functioning (49.40 ± 34.70) and physical symptoms (46.74 ± 29.36). EQ‐5D‐5L, EQ VAS, DLQI, DLQI‐R and Skindex‐16 total scores had moderate or strong correlations with each other (range: |0.487| to |0.993|), weak or moderate correlations with HS‐PGA (|0.350| to |0.433|) and weak correlations with MSS (|0.324| to |0.389|). DLQI‐R slightly outperformed DLQI both in terms of convergent and known‐groups validity. Being female, lower education level, more severe disease and genital involvement were associated with worse HRQoL (P &lt; 0.05). Conclusion This study provides high‐quality evidence that among skin‐specific outcomes, the DLQI, DLQI‐R and Skindex‐16, and among generic instruments, the EQ‐5D‐5L are suitable to be used in HS patients. In future research, we recommend the use of existing well‐validated HRQoL tools instead of developing new measures for each study. The development of composite measures that combine physician‐ and patient‐reported outcomes is not supported by evidence in HS. [Correction added on 25 July 2020, after first online publication: in the section, the ± signs were missing and have been added to this version.]</description><subject>Cross-Sectional Studies</subject><subject>Female</subject><subject>Hidradenitis Suppurativa</subject><subject>Humans</subject><subject>Psychometrics</subject><subject>Quality of Life</subject><subject>Surveys and Questionnaires</subject><issn>0926-9959</issn><issn>1468-3083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kMtOwkAUhidGI4gufAEzS00ozK1DZ2kAFdPE4IVtM3SmYbC0tdOK7HwEn9EncaDozrM41y9_cn4AzjHqYRf9pXrvYc4ZOQBtzHjgURTQQ9BGgnBPCF-0wIm1S4QQxn5wDFqUcBwgQtognsnUKFNtYJ7A8fT788sfbVPYhU-vJlP6w02Yd-EonE6gzNSucbtHaDJYyMrorLJwbaoFXBhVSqUzUxkLbV0Udenu7_IUHCUytfpsXzvg5Wb8PLzzwofbyfA69GLKEfF8GrNYUqqJT4Wmvi9ZEOAkUXNEE5lw7D5xYCy0ZgwrpRjCOkZiwJkIxIDRDrhsdIsyf6u1raKVsbFOU5npvLYRYQRhhkhAHXrVoHGZW1vqJCpKs5LlJsIo2noaOU-jnaeOvdjL1vOVVn_kr4kO6DfA2qR6879SdD-aNZI_QEuBbQ</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Gergely, L.H.</creator><creator>Gáspár, K.</creator><creator>Brodszky, V.</creator><creator>Kinyó, Á.</creator><creator>Szegedi, A.</creator><creator>Remenyik, É.</creator><creator>Kiss, N.F.</creator><creator>Bató, A.</creator><creator>Péntek, M.</creator><creator>Gulácsi, L.</creator><creator>Sárdy, M.</creator><creator>Bánvölgyi, A.</creator><creator>Wikonkál, N.</creator><creator>Rencz, F.</creator><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7071-1364</orcidid><orcidid>https://orcid.org/0000-0001-6530-7052</orcidid><orcidid>https://orcid.org/0000-0003-2109-9014</orcidid><orcidid>https://orcid.org/0000-0003-4306-5093</orcidid><orcidid>https://orcid.org/0000-0002-0973-5228</orcidid><orcidid>https://orcid.org/0000-0002-1450-4790</orcidid><orcidid>https://orcid.org/0000-0002-6095-2295</orcidid><orcidid>https://orcid.org/0000-0001-5266-4667</orcidid><orcidid>https://orcid.org/0000-0001-9674-620X</orcidid><orcidid>https://orcid.org/0000-0001-9636-6012</orcidid><orcidid>https://orcid.org/0000-0002-9285-8746</orcidid><orcidid>https://orcid.org/0000-0002-9947-1755</orcidid><orcidid>https://orcid.org/0000-0003-4949-8711</orcidid></search><sort><creationdate>202011</creationdate><title>Validity of EQ‐5D‐5L, Skindex‐16, DLQI and DLQI‐R in patients with hidradenitis suppurativa</title><author>Gergely, L.H. ; Gáspár, K. ; Brodszky, V. ; Kinyó, Á. ; Szegedi, A. ; Remenyik, É. ; Kiss, N.F. ; Bató, A. ; Péntek, M. ; Gulácsi, L. ; Sárdy, M. ; Bánvölgyi, A. ; Wikonkál, N. ; Rencz, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3602-53c4ca33e2539e355a4881ffdb03faf61995360c9ee441ddd401ec09764989743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cross-Sectional Studies</topic><topic>Female</topic><topic>Hidradenitis Suppurativa</topic><topic>Humans</topic><topic>Psychometrics</topic><topic>Quality of Life</topic><topic>Surveys and Questionnaires</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gergely, L.H.</creatorcontrib><creatorcontrib>Gáspár, K.</creatorcontrib><creatorcontrib>Brodszky, V.</creatorcontrib><creatorcontrib>Kinyó, Á.</creatorcontrib><creatorcontrib>Szegedi, A.</creatorcontrib><creatorcontrib>Remenyik, É.</creatorcontrib><creatorcontrib>Kiss, N.F.</creatorcontrib><creatorcontrib>Bató, A.</creatorcontrib><creatorcontrib>Péntek, M.</creatorcontrib><creatorcontrib>Gulácsi, L.</creatorcontrib><creatorcontrib>Sárdy, M.</creatorcontrib><creatorcontrib>Bánvölgyi, A.</creatorcontrib><creatorcontrib>Wikonkál, N.</creatorcontrib><creatorcontrib>Rencz, F.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gergely, L.H.</au><au>Gáspár, K.</au><au>Brodszky, V.</au><au>Kinyó, Á.</au><au>Szegedi, A.</au><au>Remenyik, É.</au><au>Kiss, N.F.</au><au>Bató, A.</au><au>Péntek, M.</au><au>Gulácsi, L.</au><au>Sárdy, M.</au><au>Bánvölgyi, A.</au><au>Wikonkál, N.</au><au>Rencz, F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Validity of EQ‐5D‐5L, Skindex‐16, DLQI and DLQI‐R in patients with hidradenitis suppurativa</atitle><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle><addtitle>J Eur Acad Dermatol Venereol</addtitle><date>2020-11</date><risdate>2020</risdate><volume>34</volume><issue>11</issue><spage>2584</spage><epage>2592</epage><pages>2584-2592</pages><issn>0926-9959</issn><eissn>1468-3083</eissn><abstract>Background Numerous generic, skin‐ and disease‐specific health‐related quality of life (HRQoL) measures are available for patients with hidradenitis suppurativa (HS). Yet, robust psychometric evidence is lacking in many aspects of these outcome measures. Objectives We sought to determine convergent and known‐groups validity of multiple generic and skin‐specific HRQoL measures and to identify predictors of impaired HRQoL in patients with HS. Methods Between 2017 and 2019, a multicentre cross‐sectional study was carried out involving 200 consecutive HS patients. HRQoL outcomes included the EQ‐5D‐5L, EQ visual analogue scale (EQ VAS), Skindex‐16, Dermatology Life Quality Index (DLQI) and DLQI‐Relevant (DLQI‐R). Disease severity was graded by HS‐Physician’s Global Assessment (HS‐PGA) scale and the Modified Sartorius scale (MSS). Results Overall, 77%, 56%, 51%, 46% and 28% reported problems in the pain/discomfort, usual activities, anxiety/depression, mobility and self‐care dimensions of EQ‐5D‐5L. Mean ± SD EQ VAS, DLQI and DLQI‐R scores were 64.29 ± 22.68, 11.75 ± 8.11 and 12.19 ± 8.33, respectively. Skindex‐16 responses indicated that the emotional burden of HS (64.55 ± 29.28) far exceeded those of functioning (49.40 ± 34.70) and physical symptoms (46.74 ± 29.36). EQ‐5D‐5L, EQ VAS, DLQI, DLQI‐R and Skindex‐16 total scores had moderate or strong correlations with each other (range: |0.487| to |0.993|), weak or moderate correlations with HS‐PGA (|0.350| to |0.433|) and weak correlations with MSS (|0.324| to |0.389|). DLQI‐R slightly outperformed DLQI both in terms of convergent and known‐groups validity. Being female, lower education level, more severe disease and genital involvement were associated with worse HRQoL (P &lt; 0.05). Conclusion This study provides high‐quality evidence that among skin‐specific outcomes, the DLQI, DLQI‐R and Skindex‐16, and among generic instruments, the EQ‐5D‐5L are suitable to be used in HS patients. In future research, we recommend the use of existing well‐validated HRQoL tools instead of developing new measures for each study. The development of composite measures that combine physician‐ and patient‐reported outcomes is not supported by evidence in HS. [Correction added on 25 July 2020, after first online publication: in the section, the ± signs were missing and have been added to this version.]</abstract><cop>England</cop><pmid>32618022</pmid><doi>10.1111/jdv.16642</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-7071-1364</orcidid><orcidid>https://orcid.org/0000-0001-6530-7052</orcidid><orcidid>https://orcid.org/0000-0003-2109-9014</orcidid><orcidid>https://orcid.org/0000-0003-4306-5093</orcidid><orcidid>https://orcid.org/0000-0002-0973-5228</orcidid><orcidid>https://orcid.org/0000-0002-1450-4790</orcidid><orcidid>https://orcid.org/0000-0002-6095-2295</orcidid><orcidid>https://orcid.org/0000-0001-5266-4667</orcidid><orcidid>https://orcid.org/0000-0001-9674-620X</orcidid><orcidid>https://orcid.org/0000-0001-9636-6012</orcidid><orcidid>https://orcid.org/0000-0002-9285-8746</orcidid><orcidid>https://orcid.org/0000-0002-9947-1755</orcidid><orcidid>https://orcid.org/0000-0003-4949-8711</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0926-9959
ispartof Journal of the European Academy of Dermatology and Venereology, 2020-11, Vol.34 (11), p.2584-2592
issn 0926-9959
1468-3083
language eng
recordid cdi_proquest_miscellaneous_2420140283
source Wiley Online Library - AutoHoldings Journals; MEDLINE
subjects Cross-Sectional Studies
Female
Hidradenitis Suppurativa
Humans
Psychometrics
Quality of Life
Surveys and Questionnaires
title Validity of EQ‐5D‐5L, Skindex‐16, DLQI and DLQI‐R in patients with hidradenitis suppurativa
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T02%3A35%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Validity%20of%20EQ%E2%80%905D%E2%80%905L,%20Skindex%E2%80%9016,%20DLQI%20and%20DLQI%E2%80%90R%20in%20patients%20with%20hidradenitis%20suppurativa&rft.jtitle=Journal%20of%20the%20European%20Academy%20of%20Dermatology%20and%20Venereology&rft.au=Gergely,%20L.H.&rft.date=2020-11&rft.volume=34&rft.issue=11&rft.spage=2584&rft.epage=2592&rft.pages=2584-2592&rft.issn=0926-9959&rft.eissn=1468-3083&rft_id=info:doi/10.1111/jdv.16642&rft_dat=%3Cproquest_cross%3E2420140283%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2420140283&rft_id=info:pmid/32618022&rfr_iscdi=true